The Optimal Antithrombotic Strategy for Post-stroke Patients with Atrial Fibrillation and Extracranial Artery Stenosis-a Nationwide Cohort Study

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2024 Mar 13

PMID 38475752

Authors

Chuan-Tsai Tsai

Yi-Hsin Chan

Jo-Nan Liao

Tzeng-Ji Chen

Gregory Y H Lip

Shih-Ann Chen

Tze-Fan Chao

Affiliations

Soon will be listed here.

Abstract

Background: In post-stroke atrial fibrillation (AF) patients who have indications for both oral anticoagulant (OAC) and antiplatelet agent (AP), e.g., those with carotid artery stenosis, there is debate over the best antithrombotic strategy. We aimed to compare the risks of ischemic stroke, composite of ischemic stroke/major bleeding and composite of ischemic stroke/intracranial hemorrhage (ICH) between different antithrombotic strategies.

Methods: This study included post-stroke AF patients with and without extracranial artery stenosis (ECAS) (n = 6390 and 28,093, respectively) identified from the Taiwan National Health Insurance Research Database. Risks of clinical outcomes and net clinical benefit (NCB) with different antithrombotic strategies were compared to AP alone.

Results: The risk of recurrent ischemic stroke was higher for patients with ECAS than those without (12.72%/yr versus 10.60/yr; adjusted hazard ratio [aHR] 1.104, 95% confidence interval [CI] 1.052-1.158, p < 0.001). For patients with ECAS, when compared to AP only, non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy was associated with lower risks for ischaemic stroke (aHR 0.551, 95% CI 0.454-0.669), the composite of ischaemic stroke/major bleeding (aHR 0.626, 95% CI 0.529-0.741) and the composite of ischaemic stroke/ICH (aHR 0.577, 95% CI 0.478-0.697), with non-significant difference for major bleeding and ICH. When compared to AP only, warfarin monotherapy was associated with higher risks of major bleeding (aHR 1.521, 95% CI 1.231-1.880), ICH (aHR 2.045, 95% CI 1.329-3.148), and the composite of ischaemic stroke and major bleeding. With combination of AP plus warfarin, there was an increase in ischaemic stroke, major bleeding, and the composite outcomes, when compared to AP only. NOAC monotherapy was the only approach associated with a positive NCB, while all other options (warfarin, combination of AP-OAC) were associated with negative NCB.

Conclusions: For post-stroke AF patients with ECAS, NOAC monotherapy was associated with lower risks of adverse outcomes and a positive NCB. Combination of AP with NOAC or warfarin did not offer any benefit, but more bleeding especially with AP-warfarin combination therapy.

References

Cheng C, Kao Y, Lin S, Lee C, Lai M . Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20(3):236-42. DOI: 10.1002/pds.2087. View

Lin L, Lee C, Yu C, Tsai C, Lai L, Hwang J . Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. Atherosclerosis. 2011; 217(1):292-5. DOI: 10.1016/j.atherosclerosis.2011.03.033. View

Tsai C, Liao J, Chiang C, Lin Y, Chang S, Lo L . Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. JAMA Netw Open. 2020; 3(6):e206424. PMC: 7265096. DOI: 10.1001/jamanetworkopen.2020.6424. View

Vitalis A, Nirantharakumar K, Thayakaran R, Vohra R, Kay M, Shantsila A . The Impact of Atrial Fibrillation on Outcomes of Peripheral Arterial Disease: Analysis of Routinely Collected Primary Care Data. Am J Med. 2021; 135(4):488-492. DOI: 10.1016/j.amjmed.2021.10.021. View

Buckley B, Harrison S, Hill A, Underhill P, Lane D, Lip G . Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. Stroke. 2022; 53(5):1759-1763. DOI: 10.1161/STROKEAHA.121.037316. View

Chang C, Lee Y, Tsai C, Chang S, Chung Y, Lin M . Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014; 232(1):224-30. DOI: 10.1016/j.atherosclerosis.2013.11.036. View

Hsieh C, Chen C, Li C, Lai M . Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2013; 114(3):254-9. DOI: 10.1016/j.jfma.2013.09.009. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

Guo Y, Lane D, Chen Y, Lip G . Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. Am J Med. 2020; 133(10):1195-1202.e2. DOI: 10.1016/j.amjmed.2020.03.019. View

10.

Gorog D, Gue Y, Chao T, Fauchier L, Ferreiro J, Huber K . Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute.... Europace. 2022; 24(11):1844-1871. PMC: 11636575. DOI: 10.1093/europace/euac020. View

11.

Lip G, Collet J, Haude M, Byrne R, Chung E, Fauchier L . 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the.... Europace. 2018; 21(2):192-193. DOI: 10.1093/europace/euy174. View

12.

Chao T, Chiang C, Chan Y, Liao J, Chen T, Lip G . Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm. 2021; 18(6):871-877. DOI: 10.1016/j.hrthm.2021.02.018. View

13.

Singer D, Chang Y, Fang M, Borowsky L, Pomernacki N, Udaltsova N . The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151(5):297-305. PMC: 2777526. DOI: 10.7326/0003-4819-151-5-200909010-00003. View

14.

Noubiap J, Agbaedeng T, Tochie J, Nkeck J, Ndoadoumgue A, Fitzgerald J . Meta-Analysis Comparing the Frequency of Carotid Artery Stenosis in Patients With Atrial Fibrillation and Vice Versa. Am J Cardiol. 2020; 138:72-79. DOI: 10.1016/j.amjcard.2020.10.017. View

15.

Lee S, Rhee T, Kang D, Choi E, Oh S, Lip G . Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. Am J Cardiol. 2019; 124(6):879-885. DOI: 10.1016/j.amjcard.2019.05.072. View

16.

Komen J, Heerdink E, Klungel O, Mantel-Teeuwisse A, Forslund T, Wettermark B . Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother. 2020; 7(FI1):f72-f80. PMC: 8117431. DOI: 10.1093/ehjcvp/pvaa017. View

17.

Yoon M, Yang P, Jang E, Yu H, Kim T, Uhm J . Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thromb Haemost. 2019; 119(10):1695-1703. DOI: 10.1055/s-0039-1693516. View

18.

Chao T, Chiang C, Chen T, Liao J, Tuan T, Chen S . Clinical Risk Score for the Prediction of Incident Atrial Fibrillation: Derivation in 7 220 654 Taiwan Patients With 438 930 Incident Atrial Fibrillations During a 16-Year Follow-Up. J Am Heart Assoc. 2021; 10(17):e020194. PMC: 8649261. DOI: 10.1161/JAHA.120.020194. View

19.

Chao T, Joung B, Takahashi Y, Lim T, Choi E, Chan Y . 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2021; 122(1):20-47. PMC: 8763451. DOI: 10.1055/s-0041-1739411. View

20.

Cheng W, Chiang C, Lin Y, Chang S, Lo L, Hu Y . Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (≥85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study. Mayo Clin Proc. 2021; 96(1):52-65. DOI: 10.1016/j.mayocp.2020.08.042. View